Bionovo to Present at the BMO Capital Markets Ninth Annual Focus on Healthcare Conference

EMERYVILLE, Calif., July 29 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI), a drug discovery and development company focused on the unmet needs in women's health and oncology, today announced that Dr. Mary Tagliaferri, President and Chief Medical Officer, and Tom Chesterman, Senior Vice President and CFO, will be presenting at the BMO Capital Markets Ninth Annual Focus on Healthcare Conference at 1:45 p.m. EDT on Wednesday, August 5, 2009. The event will be held at the Millennium Broadway Hotel in New York City.

Interested parties can access a live webcast of the presentation by visiting http://www.bmocm.com/conferences/2009healthcare/webcast/. A replay will be available for 6 months following the conference.

About Bionovo, Inc.

Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

SOURCE  Bionovo, Inc.



    -0-                           07/29/2009

    /CONTACT:  Claire Fong or Tom Chesterman, Both of Bionovo, Inc.,

+1-510-601-2000, investor@bionovo.com; Investors, Joe Diaz, Robert Blum or Joe

Dorame, Lytham Partners, LLC, +1-602-889-9700, bnvi@lythampartners.com, For

Bionovo, Inc./

    /Web Site:  http://www.bionovo.com /

    (BNVI)



CO:  Bionovo, Inc.



ST:  California

IN:  MTC HEA

SU:  TDS



PR

-- SF53434 --

5034 07/29/2009 09:00 EDT http://www.prnewswire.com